Please ensure Javascript is enabled for purposes of website accessibility

Why AMAG Pharmaceuticals Struggled Again in Q4

By Keith Speights - Mar 4, 2020 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker had more bad news than good news in its latest quarterly update.

When AMAG Pharmaceuticals (AMAG) reported its third-quarter results in November, the drugmaker's financial numbers were overshadowed by an FDA panel recommendation that one of its biggest-selling drugs, Makena, be withdrawn from the market. There hasn't been very much good news for the company since then.

AMAG announced its 2019 fourth-quarter and full-year results before the market opened on Wednesday, and there still wasn't a lot of good news. Here are the highlights from AMAG's Q4 update.

Syringe in one hand and a vial in the other hand, both gloved.

Image source: Getty Images.

By the numbers

AMAG Pharmaceuticals reported Q4 revenue of $89.7 million, up nearly 2% from the prior-year total of $88.1 million. This result topped the consensus Wall Street revenue estimate of $88.39 million.

The company announced a net loss of $200 million, or $5.89 per share, in the fourth quarter based on generally accepted accounting principles (GAAP). This represented a huge decline from the loss of $22.3 million, or $0.60 per share, reported in Q4 2018. Analysts' average estimate predicted a net loss of $0.36 per share.

AMAG posted an adjusted EBITDA loss of $5.8 million in the fourth quarter. This figure was significantly worse than the company's positive adjusted EBITDA of $1.5 million in the prior-year period.

The drugmaker ended the fourth quarter with cash, cash equivalents, and short-term investments of $171.8 million. 

Behind the numbers

Probably the best news for AMAG in Q4 was its collaboration revenue totaled $16.3 million. This amount stemmed from the company's termination and settlement agreement with Daiichi Sankyo. Without this settlement, AMAG's revenue would have taken a nosedive in the fourth quarter compared to the prior-year period.

The company also reported solid sales growth for anemia drug Feraheme, with revenue jumping 18.5% year over year to $41.7 million. Sales for vaginal insert Intrarosa climbed 10% year over year to $6.5 million.

However, the problems continued for progestin injection Makena. AMAG reported Q4 sales for the drug plunged 45% from the prior-year period to $25.6 million. 

AMAG's bottom line was weighed down by the company's impairment charges of $155 million. These charges related to the FDA advisory committee recommendation that Makena be withdrawn from the market and the company's decision to sell Intrarosa and hypoactive sexual desire drug Vyleesi. 

Looking ahead

The company projects sales will be between $230 million and $280 million for full-year 2020. AMAG expects non-GAAP adjusted EBITDA will come in between $20 million and $50 million.

Healthcare stocks, in general, could experience greater volatility this year with the ongoing U.S. presidential campaign. However, AMAG has even more factors that could make its shares volatile. The company is looking for a new CEO to replace William Heiden. It's trying to sell Intrarosa and Vyleesi. And AMAG is still scrambling to work with the FDA to keep Makena on the market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AMAG Pharmaceuticals, Inc. Stock Quote
AMAG Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.